`571-272-7822 Entered: June 14, 2017
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`____________
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________
`
`ACRUX DDS PTY LTD. & ACRUX LIMITED
`Petitioner,
`
`v.
`
`KAKEN PHARMACEUTICAL CO., LTD. And VALEANT
`PHARMACEUTICALS INTERNATIONAL, INC.,
`Patent Owner.
`____________
`
`Case IPR2017-00190
`Patent 7,214,506 B2
`____________
`Before ERICA A. FRANKLIN, SUSAN L. C. MITCHELL, and
`ROBERT A. POLLOCK, Administrative Patent Judges.
`
`MITCHELL, Administrative Patent Judge.
`
`
`
`ORDER
`Conduct of the Proceeding
`37 C.F.R. § 42.5
`
`
`
`
`
`
`
`
`IPR2017-00190
`Patent 7,214,506 B2
`
`
`
`Acrux DDS PTY Ltd. And Acrux Limited (collectively, “Petitioner”)
`requested a conference call with the panel to seek authorization to file a motion to
`stay prosecution of Patent Owner’s Reissue Application No. 15/405,171, filed
`January 12, 2017, pending resolution of this inter partes proceeding. Petitioner
`indicated that Patent Owner will oppose such a request. A conference call was
`held on June 13, 2017, between respective counsel for the parties and
`Judges Mitchell, Franklin, and Pollock, to discuss Petitioner’s request. Petitioner
`engaged a court reporter to record the conference call. Petitioner confirmed that it
`promptly will file the transcript in the record when it is available.
`Petitioner stated that the claims at issue in the reissue application are similar
`to the claims at issue in this inter partes proceeding, which may cause inconsistent
`outcomes, a duplication of effort by the Office, and unnecessary effort by the
`parties, if the two proceedings go forward in parallel. Although Patent Owner
`agreed that at least two claims in the reissue application are very similar to claims
`at issue in this inter partes proceeding, Patent Owner stated that many of the
`dependent claims are patentably distinct from the claims at issue in this inter partes
`proceeding and do not implicate a possible inconsistent outcome with any decision
`in this proceeding, nor require duplicative effort of the Office or the parties. Patent
`Owner also indicated that it would be prejudiced by a delay in the reissue
`application process as it anticipates ANDA litigation in the coming year and
`staying the reissue application process would unduly delay resolution of the
`patentability of claims in the reissue proceeding.
`During the conference call, we granted Petitioner’s request for authorization
`to file a motion to stay Patent Owner’s reissue proceeding.
`
`
`
`
`2
`
`
`
`IPR2017-00190
`Patent 7,214,506 B2
`
`
`
`ORDER
`
`It is
`ORDERED that the Petitioner’s request for authorization to file a motion to
`stay Reissue Application No. 15/405,171 is granted;
`FURTHER ORDERED that the Petitioner’s motion to stay is limited to five
`pages in length and must be filed no later than 10 calendar days from the entry of
`this order;
`FURTHER ORDERED that Patent Owner’s opposition is limited to five
`pages in length and must be filed no later than 10 calendar days from the filing of
`Petitioner’s motion to stay;
`FURTHER ORDERED that Petitioner may file a reply limited to three pages
`in length no later than 5 calendar days from the filing of Patent Owner’s opposition
`to the motion to stay; and
`FURTHER ORDERED that Petitioner will file in the record the transcript of
`the conference call when available.
`
`
`
`
`
`
`
`3
`
`
`
`IPR2017-00190
`Patent 7,214,506 B2
`
`
`For PETITIONER:
`E. Anthony Figg
`Aydin H. Harston
`ROTHWELL FIGG, ERNST & MANBECK, P.C.
`effig@rothwellfigg.com
`aharston@rothwellfigg.com
`litigationparalegals@rothwellfigg.com
`
`
`
`
`For PATENT OWNER:
`
`John D. Livingstone
`Naoki Yoshida
`FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP
`KakenIPR@finnegan.com
`
`
`Toan P. Vo
`Valeant Pharmaceuticals North America LLC
`Toan.vo@bausch.com
`
`
`
`
`
`
`4
`
`